UBS Asset Management Americas Inc. cut its holdings in Qiagen NV (NASDAQ:QGEN) by 3.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 71,992 shares of the company’s stock after selling 2,403 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in Qiagen were worth $2,227,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of the stock. Bronfman E.L. Rothschild L.P. grew its position in shares of Qiagen by 50.8% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 11,451 shares of the company’s stock valued at $354,000 after purchasing an additional 3,860 shares during the period. OxFORD Asset Management LLP grew its position in shares of Qiagen by 6.7% in the 3rd quarter. OxFORD Asset Management LLP now owns 81,216 shares of the company’s stock valued at $2,558,000 after purchasing an additional 5,116 shares during the period. Lourd Capital LLC acquired a new position in shares of Qiagen in the 4th quarter valued at approximately $223,000. Hartford Investment Management Co. acquired a new position in shares of Qiagen in the 3rd quarter valued at approximately $231,000. Finally, Trexquant Investment LP acquired a new position in shares of Qiagen in the 3rd quarter valued at approximately $234,000. Institutional investors and hedge funds own 62.23% of the company’s stock.
Several equities analysts recently issued reports on the company. BidaskClub lowered Qiagen from a “buy” rating to a “hold” rating in a research report on Thursday. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a research report on Monday, January 22nd. Commerzbank reiterated a “buy” rating on shares of Qiagen in a research report on Friday, January 19th. Zacks Investment Research upgraded Qiagen from a “sell” rating to a “hold” rating in a research report on Tuesday, February 6th. Finally, Evercore ISI assumed coverage on Qiagen in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $35.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $35.33.
Shares of Qiagen NV (NASDAQ:QGEN) opened at $34.00 on Friday. The company has a market capitalization of $7,770.00, a P/E ratio of -340.00, a price-to-earnings-growth ratio of 1.93 and a beta of 0.98. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.07 and a quick ratio of 4.59. Qiagen NV has a 12 month low of $27.74 and a 12 month high of $36.34.
Qiagen (NASDAQ:QGEN) last released its earnings results on Wednesday, January 31st. The company reported $0.43 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.01. The firm had revenue of $396.86 million for the quarter, compared to analysts’ expectations of $394.48 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. equities research analysts expect that Qiagen NV will post 1.34 earnings per share for the current fiscal year.
Qiagen announced that its board has approved a stock buyback plan on Wednesday, January 31st that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.
COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/18/ubs-asset-management-americas-inc-has-2-23-million-stake-in-qiagen-nv-qgen.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.